Rafael (RFL) said Wednesday that its $25 million rights offering resulted in subscriptions for 3.13 million class B common shares at an exercise price of $1.28 per share, generating gross proceeds of about $4 million.
Rafael's president and CEO, Howard Jonas, and his affiliates will purchase the unsubscribed shares for an aggregate amount of about $21 million.
Jonas said the proceeds will provide additional capital for regulatory approval efforts and the potential launch of Trappsol Cyclo, contingent on a positive interim result from the 48-week interim analysis of the phase 3 clinical trial for Niemann-Pick Disease Type C1.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。